More on MRK
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $147.98 |
|
|||
| Open | $148.06 | ||||
| 52 Wk High | $65.46 | ||||
| 52 Wk Low | $47.97 | ||||
| Day High | $149.98 | ||||
| Day Low | $147.48 | ||||
| P/E | 101.21 | ||||
| EPS | $1.47 | ||||
| Volume | 8,290,254 | ||||
- Merck and Daiichi Sankyo withdraw lung cancer drug application
- Ifinatamab Deruxtecan Biologics License Application for Certain Patients with Previously Treated Extensive-Stage Small Cell Lung Cancer Voluntarily Withdrawn
- FDA approves Merck and Eisai kidney cancer combination therapy
- U.S. FDA Approves WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC)
- Merck's remigromig meets primary endpoint in DME phase 2b/3 trial
- Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
- Merck (MRK) Reiterated at Neutral by Cantor Fitzgerald
- FDA updates Merck's Winrevair label with early PAH trial data
- U.S. FDA Approves Update to the Label for WINREVAIR™ (sotatercept-csrk) to Include Data from the Phase 3 HYPERION Trial Evaluating Adults Recently Diagnosed with Pulmonary Arterial Hypertension (PAH
- Japan approves Merck's subcutaneous pembrolizumab for all Keytruda uses
Entities mentioned with MRK
- Twitter | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Earnings | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
